Preclinical CRO Lovelace Biomedical Names Dr. Andrew Alexander Senior Director of Preclinical Toxicology
Research_Facility
[Albuquerque, N.M. – 2/5/2026] — Lovelace Biomedical, a not-for-profit preclinical contract research organization (CRO) that helps pharma, biotech, and federal partners generate the early-stage data required to advance therapies toward clinical testing, has appointed Andrew Alexander, DVM, PhD, MBA, DABT, Senior Director of Preclinical Toxicology. In this role, he will focus on operations and scientific rigor across Lovelace’s preclinical research ... Read More The post Preclinical CRO Lovelace